ReviewOTO open
Laryngeal Clear Cell Carcinoma: A Systematic Review.
Review in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Laryngeal clear cell carcinoma (LCCC) is an exceedingly rare tumor. Current literature on LCCC is limited to case reports with little comprehensive data available. This systematic review aims to analyze existing literature to better characterize LCCC and to identify trends in presentation, treatment, and survival. Data Sources: A literature search of PubMed, MedLine, and Embase was conducted. Review Methods: A systematic review of LCCC cases from 1976 to 2024 was performed. Data extraction followed PRISMA guidelines. Included studies were those describing adult or pediatric patients pathologically diagnosed with LCCC. Excluded studies were those describing nonclear cell pathology, nonlaryngeal location, or nonprimary clear cell carcinoma. Results: In total, 7 studies (n = 9 patients) were included in the analysis. Males (77.7%) were more commonly affected, with an average patient age of 56.5 years. The supraglottis was the most frequently involved subsite (66.6%). Most patients presented with advanced locoregional disease. Surgery alone was the most common treatment (66.6%), followed by chemoradiation (22.2%) and surgery with adjuvant chemoradiation (11.1%). Disease recurrence occurred in 55.5% of cases. Four patients (44.4%) died due to the disease, with an average survival of 9.3 months. Conclusion: LCCC is a rare tumor often presenting as a supraglottic mass with cervical metastasis. Patients underwent various treatments with surgery, chemoradiation, or a combination of both. Reported survival was generally poor, emphasizing the aggressive nature of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.